Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GBA1 | P04062 | 8/20 | 0.74 |
| ▸ | GLB1 | P16278 | 7/20 | 0.74 |
| ▸ | GBA2 | Q9HCG7 | 3/20 | 0.74 |
| ▸ | GUSB | P08236 | 1/20 | 0.51 |
| ▸ | GBA3 | Q9H227 | 1/20 | 0.45 |
| ▸ | SPHK1 | Q9NYA1 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18191975 | 0.86 | GBA1 (1.00) | GBA1GLB1GBA2GUSBSPHK1 | |
| SCHEMBL1894899 | 0.86 | GBA1 (1.00) | GBA1GLB1GBA2GUSBSPHK1 | |
| SCHEMBL13309999 | 0.86 | GBA1 (1.00) | GBA1GLB1GBA2GUSBSPHK1 | |
| SCHEMBL3501177 | 0.86 | GBA1 (1.00) | GBA1GLB1GBA2GUSBSPHK1 | |
| SCHEMBL3502233 | 0.86 | GBA1 (1.00) | GBA1GLB1GBA2GUSBSPHK1 | |
| SCHEMBL15704037 | 0.86 | GBA1 (1.00) | GBA1GLB1GBA2GUSBSPHK1 | |
| SCHEMBL1894910 | 0.86 | GBA1 (1.00) | GBA1GLB1GBA2GUSBSPHK1 | |
| SCHEMBL1895709 | 0.86 | GBA1 (1.00) | GBA1GLB1GBA2GUSBSPHK1 | |
| SCHEMBL14312301 | 0.86 | GBA1 (1.00) | GBA1GLB1GBA2GUSBSPHK1 | |
| SCHEMBL1895630 | 0.86 | GBA1 (1.00) | GBA1GLB1GBA2GUSBSPHK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100189708-A1 | HYDROXY PIPERIDINE DERIVATIVES TO TREAT GAUCHER DISEASE | AMICUS THERAPEUTICS, INC. (US) | 2010-07-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100189708-A1 | HYDROXY PIPERIDINE DERIVATIVES TO TREAT GAUCHER DISEASE | GBA1, GAA, GBA2 | GBA1 1/4885GLB1 60/4885GBA2 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.